The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Review Article

Alpelisib-Induced Hyperglycemia in PIK3CA+ Breast Cancer Patients

Authors: Anika Annoor, MBBS, Mariya Rahman Marzan, MBBS, MPH, Raisa Binte Iqbal, MBBS, Aysha Ferdausi, MBBS, Arowa Yasmeen, PhD, Parisa Tarannum, MBBS, Preethi John, MD

Abstract

Alpelisib is a phosphatidylinositol 3-kinase inhibitor approved by the US Food and Drug Administration for the treatment of hormone receptor–positive metastatic breast cancer with PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α) mutation. In recent years a number of adverse effects have been observed to be associated with this therapy, the most notable of which is hyperglycemia. A literature search was conducted to include case studies, case series, systematic reviews, and meta-analyses within the last 10 years that evaluated patients with PIK3CA-mutated hormone receptor–positive, human epidermal growth factor receptor 2 negative metastatic breast cancer. Hyperglycemia was a notable adverse effect that was found in the majority of patients without preexisting diabetes mellitus. Patients with hyperglycemia were in the high-risk groups of advanced age, prediabetes mellitus or history of insulin resistance, increased body mass index, increased blood monocyte count, and increased hemoglobin A1c (glycated hemoglobin). Hyperglycemia was manageable with antihyperglycemic agents and dose modification/discontinuation of alpelisib with no severe progression. Other notable adverse effects were rash, stomatitis, diarrhea, pneumonitis, reduced appetite, elevated liver enzymes, nausea, fatigue, and rare reports of diabetic ketoacidosis. This literature review aims to highlight the incidence and risk factors of alpelisib-induced hyperglycemia in greater depth.

 
Posted in: Breast Cancer21

Full Article

Having trouble viewing the article content below? Click here to open it directly.

References

1. Pla Peris B, Arranz Martin A, Ballesteros García A, et al. Alpelisib-induced diabetes mellitus: case report, pharmacodynamics and management considerations. Front Endocrinol (Lausanne) 2022;13:802612.
 
2. Shen S, Chen Y, Carpio A, et al. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer. Cancer 2023;129:3854–3861.
 
3. Donahue S, Santos Fulgencio G. PI3Kinhibitors and adverse events: optimizing patient care for the treatment of advanced breast cancer. Clin J Oncol Nurs 2020;24:673–680.
 
4. Fuso P, Muratore M, D’Angelo T,et al. PI3K inhibitors in advanced breast cancer: the past,the present, new challenges and future perspectives. Cancers (Basel) 2022;14:2161.
 
5. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019;380:1929–1940.
 
6. André F, Ciruelos EM, Juric D,et al .Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021;32:208–217.
 
7. Drullinsky PR, Hurvitz SA. Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. Breast Cancer Res Treat 2020;181: 233–248.
 
8. Vernieri C, Corti F, Nichetti F, et al. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. Breast Cancer Res 2020;22:33.
 
9. Juric D, Janku F, Rodón J, et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CAwild-type estrogen receptor–positive advanced breast cancer: a Phase 1b clinical trial. JAMA Oncol 2019;5:e184475.
 
10. Abufaied M, Jumbo U, Alqalalwah A, et al. Alpelisib-induced diabetic ketoacidosis in a patient with metastatic breast cancer. Cureus 2021;13:e19441.
 
11. Ge X, Behrendt CE, Yost SE, et al. Predicting hyperglycemia among patients receiving alpelisib plus fulvestrant for metastatic breast cancer. Oncologist 2023;28:e488–e492.
 
12. Hanker AB, Kaklamani V, Arteaga CL. Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors. Cancer Discov 2019;9:482–491.
 
13. Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrantin patients with HR-positive advanced breast cancer. Ann Oncol 2020;31:1001–1010.
 
14. Nunnery SE, Mayer IA. Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol 2019;30(Suppl_10):x21–x26.
 
15. Ekanayake PS, Gerwer JE, McCowen KC. Alpelisib-induced hyperglycemia—a small case series. J Endocr Soc 2021;5(Suppl 1):A365–A366.
 
16. Farah SJ, Masri N, Ghanem H, Azar M. Diabetic ketoacidosis associated with alpelisib treatment of metastatic breast cancer. AACE Clin Case Rep 2020;6:e349–e351.
 
17. Ekanayake PS, Gerwer J, McCowen K. Alpelisib-induced hyperglycemia. Acta Endocrinol (Buchar) 2022;18:115–117.
 
18. Godina E, Borstnar S. The association between baseline patient characteristics and alpelisib-induced hyperglycaemia in patients with HR+, HER2-, PIK3CA-mutated metastatic breast cancer. J Clin Oncol 2023;41(16_suppl):e13059.
 
19. Rodón J, Demanse D, Rugo HS, et al. A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer. Breast Cancer Res 2024;26:36.
 
20. Tankova T, Senkus E, Beloyartseva M, et al. Management strategies for hyperglycemia associated with the α-selective PI3K inhibitor alpelisib for the treatment of breast cancer. Cancers (Basel) 2022;14:1598.
 
21. US Food and Drug Administration. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf. Revised May 2019. Accessed May 18, 2024.
 
22. Noch E, YimI, Cantley L. EXTH-36. PI3K inhibition in conjunction with the ketogenic diet reduces growth and neuroinflammation in pediatric high-grade glioma. Neuro Oncol 2019; 21(Suppl 6):iii58.
 
23. Staels B. Metformin and pioglitazone: effectively treating insulin resistance. Curr Med Res Opin 2006;22(Suppl 2):S27–S37.
 
24. Alam F, Islam MA, Mohamed M, et al. Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials. Sci Rep 2019;9:5389. doi:10.1038/s41598-019-41854-2